Revenues (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue by product is summarized as follows:


	For the Three Months Ended March 31,
	2021						2020
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
Fumarate*	$	236.0	$	316.9	$	552.9	$	777.5	$	323.3	$	1,100.8
Interferon**	241.8		158.7		400.5		292.6		173.4		466.0
TYSABRI	273.3		230.0		503.3		277.7		244.7		522.4
FAMPYRA	—		26.6		26.6		—		28.3		28.3
Subtotal: MS product revenue	751.1		732.2		1,483.3		1,347.8		769.7		2,117.5

Spinal Muscular Atrophy:
SPINRAZA	148.7		371.8		520.5		235.4		329.6		565.0

Biosimilars:
BENEPALI	—		121.7		121.7		—		133.5		133.5
IMRALDI	—		57.9		57.9		—		61.6		61.6
FLIXABI	—		25.5		25.5		—		23.7		23.7
Subtotal: Biosimilar product revenue	—		205.1		205.1		—		218.8		218.8

Other:
FUMADERM	—		2.8		2.8		—		3.3		3.3
Total product revenue	$	899.8	$	1,311.9	$	2,211.7	$	1,583.2	$	1,321.4	$	2,904.6

*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.

**Interferon includes AVONEX and PLEGRIDY.

Analysis of change In reserves

An analysis of the change in reserves for discounts and allowances is summarized as follows:


(In millions)	Discounts		Contractual Adjustments		Returns		Total
Balance, December 31, 2020	$	141.4	$	1,093.0	$	41.6	$	1,276.0
Current provisions relating to sales in current year	185.1		775.7		3.8		964.6
Adjustments relating to prior years	0.9		(32.1)		1.0		(30.2)
Payments/credits relating to sales in current year	(111.8)		(284.8)		—		(396.6)
Payments/credits relating to sales in prior years	(82.8)		(562.9)		(1.7)		(647.4)
Balance, March 31, 2021	$	132.8	$	988.9	$	44.7	$	1,166.4

Total reserves included in consolidated balance sheets

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:


(In millions)	As of March 31, 2021		As of December 31, 2020
Reduction of accounts receivable	$	173.4	$	195.4
Component of accrued expense and other	993.0		1,080.6
Total revenue-related reserves	$	1,166.4	$	1,276.0

Revenues from anti-CD20 therapeutic programs

Revenue from anti-CD20 therapeutic programs are summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.


	For the Three Months Ended March 31,
(In millions)	2021		2020
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	174.1	$	341.3
Other revenue from anti-CD20 therapeutic programs	214.9		179.1
Total revenue from anti-CD20 therapeutic programs	$	389.0	$	520.4

Other revenues

Other revenue is summarized as follows:


	For the Three Months Ended March 31,
(In millions)	2021		2020
Revenue from collaborative and other relationships:
Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis	$	3.9	$	3.7
Other revenue from collaborative and other relationships	—		0.2
Other royalty and corporate revenue:
Royalty	6.2		11.4
Other corporate	83.2		94.0
Total other revenue	$	93.3	$	109.3